can you combine sglt2 and glp 1 GLP-1 & Inhibitor Combination Therapy – Bolt Pharmacy GLP1 Receptor Agonists vs SGLT2-I

Li, J., Chiew, A

For the innovator, the primary data questions are: Who has filed a P.IV against my products? What are the weak patents in my thicket? What is the patent cliff exposure of my M&A target, and how does it affect the deals NPV? For the generic and biosimilar challenger, the primary questions are: Which high-value products have thin or weak patent estates? Can we be first to file a P.IV? What API suppliers are qualified and available for our target drugs active ingredient? For institutional investors, the questions are: What is the aggregate LOE exposure in this companys commercial portfolio over the next 5 years? Is the market correctly pricing the risk that a P.IV challenge will succeed and generate an early generic? What does the biosimilar pipeline look like for the top five drugs in this Big Pharmas revenue mix? The CI Playbook for Each Market Participant Competitive intelligence in pharmaceutical patent strategy is not a single discipline it is a set of distinct analytical functions tailored to the decision-making context of each player in the LOE ecosystem

Reno, A

Tominaga K, Suzuki HI

Tetramethylpyrazine ameliorates systemic streptozotocin-induced Alzheimer-like pathology